Autobio Diagnostics

Autobio Diagnostics Co., Ltd was founded in 1998, headquartered in Zhengzhou, China. As a leading provider of comprehensive solutions for medical laboratories, Autobio specializes in R & D, production, marketing and service of clinical diagnostic products. Focusing on immunoassay, molecular, microbiology and POCT fields, Autobio helps healthcare professionals tailor treatment with fast, reliable and accurate diagnosis solution for various diseases and dysfunctions.
Autobio has a strategic vision to establish a world class technology-based operation that is committed to manufacturing and marketing products that adhere to global standards in both quality and care. Currently, Autobio has 529 product registration certificates, 322 CE marked and 528 patents. In overseas markets, Autobio’ s products have performed enormous potential, exporting to over 80 countries and regions.

Always taking product quality and sophisticated manufacturing as the first priority, Autobio’s fully Automated Chemiluminescence Immunoassay (CLIA) Analyzer and Assays have entered more than ten thousands medical institutions

all over the world. From ELISA to CLIA system based on Microparticles, Autobio is among the top IVD enterprises capable of providing comprehensive immunoassay solutions.

With profound accumulation in microbiology field, Autobio also take predominant position in blood culturing, identification, and antibiotic susceptibility testing. Among them, the Automated Mass Spectrometry Microbial Identification System Autof ms1000 ranks first in growth rate in China and maintains vigorous upward trend in overseas market by virtue of the ability to Obtained identification results within 0.1 seconds.

In the field of molecular detection, Autobio has launched the automatic nucleic acid purification and real-time fluorescent PCR analysis systems AutoMolec 3000 and AutoMolec 1600, which innovatively realizes random access and full automation of extraction and amplification. The SARS-CoV-2 reagent has obtained the NMPA certification. In addition, other molecular detection reagents such as respiratory tract and HPV will also be launched this year. In the future, Autobio will put more investment into the R&D of random automated molecular detection devices and broader assays.

Visit https://en.autobio.com.cn/ for more info.

Customer first, market orientation；

People foremost，focusing on personal development ；

Pursue excellence，persisting in optimization and innovation；

Devote to teamwork，focusing on self-contribution；

Enhance communication，appreciating the honesty ；

Be responsible to job，avoiding Buck-passing；

Obey orders，strictly following rules and regulations；

Differentiate treatment, implementing strict performance judgement.